Comparaison de distributions quelconques à l'aide d'un test non paramétrique

info:eu-repo/semantics/publishedStatistique et épidémiologi

Effect of parenteral dezocine anbd placebo in cancer pain

A double-blind, placebo-controlled crossover trial was carried out in 20 hospitalized patients with continuous pain due to cancer to assess the analgesic effectiveness and tolerance of a single intramuscular injection of 10 mg dezocine. Subjective assessments of pain, made at hourly intervals over 4 hours, showed that dezocine produces a statistically significant greater and sustained relief of pain than did placebo. Only minor side-effects were reported.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

PRINCIPE ET JUSTIFICATION DE L'ESSAI THERAPEUTIQUE

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A double-blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain

The analgesic efficacy of ketorolac tromethamine was compared to placebo in 126 patients suffering moderate or severe chronic pain due to cancer in a double-blind parallel randomized study. Ketorolac was administered intramuscularly in doses of 10, 30 or 90 mg. Pain intensity and pain relief were assessed for 6 hours by scoring standard verbal scales and an overall assessment of the medication was given by the patients and the observer on completion of the study. Each dose of ketorolac was statistically superior to placebo for the sum of pain intensity difference (SPID) but no difference was seen between the three ketorolac regimens. When the ketorolac groups are combined, there was a significantly better pain relief as compared to placebo. The global evaluation scores were also statistically superior in the ketorolac groups combined than in the placebo group. A total of 15 patients reported minor adverse events, 10 being after ketorolac doses. This study shows that single intramuscular doses of ketorolac of 10 mg and above are effective in the relief of cancer pain, and are associated with a low incidence of side-effects.SCOPUS: ar.jFLWNAinfo:eu-repo/semantics/publishe

A double-blind comparison of meptazinol with pentazocine and placebo in cancer pain

Two consecutive, double-blind crossover, single-administration trials have shown that intramuscular meptazinol, a new opioid-antagonist drug, is superior to placebo and equivalent to pentazocine in relieving chronic pain due to cancer.SCOPUS: ar.jFLWNAinfo:eu-repo/semantics/publishe

Analgesic effect of ciramadol in patients with chronic pain

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

A double-blind study of dezocine in cancer pain

A double-blind crossover comparison of intramuscular administration of 10 mg dezocine (Wy 16225), 10 mg morphine, and placebo in ten patients with cancer pain has shown that a dezocine single dose is superior to placebo in producing relief of moderate to severe pain. No side effects were observed.SCOPUS: ar.jFLWNAinfo:eu-repo/semantics/publishe

The randomized clinical trial: a prerequisite for rational therapy

The results of non randomized clinical trials in urological cancer are often contradictory because of the selection of patients which is usually biased. Such data cannot be used for planning a logical therapy for future patients. In urological cancer, randomized controlled trials are few. Moreover, antimitotic chemotherapy has not been adequately tried.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Optimal antibiotic therapy for infections in patients with cancer: prospects for the future

SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Randomized trials in cancer: a critical review by sites

xii+433hlm.;24c